Effectiveness of inactivated influenza vaccine in children by vaccine dose, 2013-18.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
09 07 2019
Historique:
received: 01 02 2019
revised: 19 05 2019
accepted: 31 05 2019
pubmed: 13 6 2019
medline: 8 9 2020
entrez: 13 6 2019
Statut: ppublish

Résumé

We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) by vaccine dose in children aged 6 months to 12 years for whom two doses are recommended in Japan to ascertain the appropriate vaccine doses. VE was assessed according to a test-negative case-control design based on rapid influenza diagnostic test (RIDT) results. Children aged 6 months to 12 years with a fever ≥38 °C who had received an RIDT in outpatient clinics of 24 hospitals were enrolled for all five seasons since 2013/14. VE by vaccine dose (none vs. once or twice, and once vs. twice) was analyzed. In the dose analysis, 20,033 children were enrolled. Both one- and two-dose regimens significantly reduced cases in preventing any influenza, influenza A, and influenza B, but there was no significant difference in adjusted VE between one- and two-dose regimens overall (adjusted OR, 0.560 [95% CI, 0.505-0.621], 0.550 [95% CI, 0.516-0.586]), 0.549 [95% CI, 0.517-0.583], and 1.014 [95% CI, 0.907-1.135], for none vs. once, none vs. twice, none vs. once or twice, and once vs. twice for any influenza, respectively). Both one- and two-dose regimens significantly reduced cases with any influenza and influenza A every season. Also, both regimens significantly reduced cases of any influenza, influenza A, and influenza B among children aged 1-12 years, especially among those aged 1-5 years. In the 2013/14, 2015/16, and 2016/17 seasons, however, only the two-dose regimen was significantly effective in preventing influenza B. Both one- and two-dose regimens significantly reduced cases involving hospitalization due to any influenza and influenza A. Both one- and two-doses regimens of IIV were effective in preventing influenza for children aged 6 months to 12 years. The two-dose regimen was more effective against influenza B in some seasons.

Identifiants

pubmed: 31186191
pii: S0264-410X(19)30747-9
doi: 10.1016/j.vaccine.2019.05.090
pii:
doi:

Substances chimiques

Influenza Vaccines 0
Vaccines, Inactivated 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4047-4054

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Masayoshi Shinjoh (M)

Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: m-shinjo@z2.keio.jp.

Norio Sugaya (N)

Department of Pediatrics, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama, 220-0012 Kanagawa, Japan; Department of Infection Control, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama, 220-0012 Kanagawa, Japan.

Munehiro Furuichi (M)

Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Eriko Araki (E)

Pediatrics, Yokohama City Municipal Hospital, 56 Okazawacho, Hodogaya-ku, Yokohama-city, Kanagawa 240-8555, Japan.

Naonori Maeda (N)

Department of Pediatrics, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro-ku, Tokyo 152-0021, Japan.

Kyohei Isshiki (K)

Department of Pediatrics, Saitama City Hospital, 2460 Mimuro, Midori-ku, Saitama-shi, Saitama 336-8522, Japan.

Takuma Ohnishi (T)

Department of Pediatrics, National Hospital Organization Saitama National Hospital, 2-1 Suwa, Wako-shi, Saitama 321-0102, Japan.

Shoko Nakamura (S)

Department of Pediatrics, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minamiohtsuka, Toshima-ku, Tokyo 170-8476, Japan.

Go Yamada (G)

Pediatrics, Saiseikai Utsunomiya Hospital, #201, 3-9-11 Nishiki, Utsunomiya-shi, Tochigi 321-0967, Japan.

Atsushi Narabayashi (A)

Department of Pediatrics, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki City, Kanagawa 210-0013, Japan.

Mitsuhiro Nishida (M)

Department of Pediatrics, Shizuoka City Shimizu Hospital, 1231 Miyakami, Shimizu-ku, Shizuoka-shi, Shizuoka 424-8636, Japan.

Nobuhiko Taguchi (N)

Department of Pediatrics, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama-shi, Kanagawa 220-8581, Japan.

Yuji Nakata (Y)

Department of Pediatrics, Nippon Koukan Hospital, 1-2-1 Koukandori, Kawasaki, Kanagawa 210-0852, Japan.

Makoto Yoshida (M)

Department of Pediatrics, Sano Kousei General Hospital, 1728 Horigome-cho, Sano City, Tochigi 327-8511, Japan.

Kenichiro Tsunematsu (K)

Department of Pediatrics, Hino Municipal Hospital, 4-3-1 Tamadaira, Hino-shi, Tokyo 191-0062, Japan.

Meiwa Shibata (M)

Division of Pediatrics, Yokohama Rosai Hospital, 3211 Kozukue-Cho, Kohoku-ku, Yokohama 222-0036, Japan.

Takeshi Munenaga (T)

Department of Pediatrics, Ota Memorial Hospital, 455-1 Oshima-chou, Ota-shi, Gumma 373-8585, Japan.

Yasuhiro Hirano (Y)

Department of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka-Shi, Kanagawa 254-0065, Japan.

Ichiro Ookawara (I)

Department of Pediatrics, Japanese Red Cross Shizuoka Hospital, 8-2 Outemachi, Aoi-ku, Shizuoka 420-0853, Japan.

Shinichiro Sekiguchi (S)

Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Yasuaki Kobayashi (Y)

Department of Pediatrics, Japanese Red Cross Ashikaga Hospital, 284-1, Yobecho, Ashikaga, Tochigi 326-0843, Japan.

Yoshio Yamaguchi (Y)

Institute of Clinical Research, Department of Infection & Allergy, National Hospital Organization Tochigi Medical Center, 1-10-37 Nakatomatsuri, Utsunomiya-shi, Tochigi 320-8580, Japan.

Naoko Yoshida (N)

Department of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Keiko Mitamura (K)

Department of Pediatrics, Eiju General Hospital, 2-23-16 Higashi-Ueno, Taito-ku, Tokyo 110-8645, Japan.

Takao Takahashi (T)

Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH